For doripenem, limited clinical data on exposed pregnancies are available. Animal studies are insufficient with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
The potential risk for human is not known. Doripenem should not be used during pregnancy unless clearly necessary.
It is not known whether doripenem is excreted in human breast milk. A study in rats has shown that doripenem and its metabolite are transferred to milk. A decision on whether to continue/discontinue breast-feeding or to continue therapy with doripenem should be made taking into account the benefit of breast-feeding to the child and the benefit of Doripenem therapy to the woman.